Therapeutic Sulphatase Engineering Services

Sulphatases are vital enzymes responsible for the hydrolysis of sulfate esters in various complex molecules, including glycosaminoglycans (GAGs) and sulfated steroids. Deficiencies in specific lysosomal sulphatases lead to severe Lysosomal Storage Diseases (LSDs), such as Mucopolysaccharidosis (MPS). While Enzyme Replacement Therapy (ERT) has been the standard of care, its efficacy is often restricted by the enzyme's low stability and catalytic activity at physiological pH, poor cellular internalization, and the development of neutralizing antibodies due to immunogenicity.

Our comprehensive enzyme engineering and optimization services are specifically tailored to address these therapeutic barriers. We leverage advanced protein design to create sulphatase variants with shifted pH profiles, enhanced endosomal escape, and reduced immunological signatures, transforming traditional ERT into a more potent and sustainable clinical solution.

Get a Quote

Clinical Challenges Engineering Focus Technology Platforms Project Flow FAQ

Challenges in Sulphatase Therapy Development

Developing effective sulphatase-based therapeutics requires overcoming several biological and pharmacological hurdles:

pH-Dependent Activity: Most natural sulphatases evolved for acidic lysosomal environments (pH ~4.5-5.0) and exhibit significantly reduced catalytic turnover at physiological pH (pH 7.4), limiting their activity in systemic circulation.
Suboptimal Cellular Uptake: Efficient delivery to target tissues requires precise glycosylation patterns (e.g., Mannose-6-Phosphate) or specific ligands to facilitate receptor-mediated endocytosis.
In Vivo Degradation: Therapeutic enzymes are susceptible to serum proteases and rapid clearance, necessitating high doses that increase treatment costs and side-effect risks.
Immunogenic Responses: Repeated administration of recombinant sulphatases can trigger immune responses, leading to the formation of anti-drug antibodies (ADAs) that neutralize the enzyme’s effect.

Our platforms integrate metabolic pathway assays and functional profiling to ensure that engineered sulphatases maintain biological relevance within the complex cellular environment.

Engineering Focus: Enhanced Therapeutic Efficacy

We apply targeted molecular engineering to redefine the therapeutic profile of sulphatases:

pH Profile Optimization

We utilize enzyme active site engineering to modify electrostatic environments, shifting the optimal activity toward neutral pH for broader therapeutic windows.

Cellular Uptake Enhancement

Engineering for improved receptor affinity and endosomal escape through the integration of cell-penetrating peptides or glyco-engineering of the protein surface.

Immune Evasion Design

Reducing immunogenicity by masking high-risk epitopes and employing enzyme stability engineering to prevent protein aggregation.

Catalytic Power Boosting

Focusing on the Formylglycine (FGly) post-translational modification essential for sulphatase activity, ensuring high-yield active enzyme production.

Technology Platforms for Sulphatase Engineering

Our optimization projects are powered by a suite of high-precision technologies:

Computer-Aided Rational Design (CARD)

We utilize CARD technology to simulate substrate binding at varying pH levels, identifying mutations that stabilize the transition state in neutral environments.

Phage-Assisted Evolution (PACE)

Using phage-assisted continuous evolution, we drive the selection of sulphatase variants that maintain structural integrity under serum-mimicking pressures.

AI-Driven Discovery

Our AI-driven enzyme discovery platforms mine metagenomic data for novel sulphatases with innate resistance to immunogenic recognition.

Cell-Surface Display

We employ cell surface display for enzyme engineering to screen for variants with superior binding affinity to target cell receptors.

Kinetic Profiling

Detailed enzyme kinetic profiling ensures the engineered variants possess the turnover rates required for effective GAG clearance.

Project Flow: Sulphatase Therapeutic Workflow

We follow a milestone-driven optimization process to deliver high-quality clinical candidates:

Consultation & Target Definition: Defining clinical targets, pH requirements, and cellular uptake milestones.
Structure-Guided Design: In-silico modeling of the sulphatase-substrate complex and identification of catalytic bottlenecks.
Library Construction & Screening: Mutagenesis and employment of microtiter plate screening to identify leads with improved pH stability.
In-Cellulo Validation: Evaluating cellular uptake and lysosomal localization in patient-derived fibroblast models.
Final Characterization: Delivery of the optimized enzyme with detailed reports on activity, stability, and predicted immunogenicity.

Our technical team maintains constant communication to align engineering goals with clinical needs. We offer comprehensive support for therapeutic development, including:

Detailed pH-profile and thermal stability data across physiological and lysosomal ranges.
Validation of post-translational modifications, particularly the FGly conversion efficiency essential for activity.
Experimental reports documenting uptake kinetics and intracellular half-life in target cell lines.

FAQ: Sulphatase Engineering

Expert answers on therapeutic enzyme design.

Why is pH optimization critical for therapeutic sulphatases?

Natural sulphatases are most active in the acidic lysosome. By shifting their activity profile toward neutral pH, we ensure the enzyme remains active in the cytoplasm and circulation, improving overall GAG degradation efficiency.

How do you improve cellular uptake in sulphatase replacement therapy?

We use protein fusion strategies and glyco-engineering to increase the density of ligands that bind to receptors like CI-MPR, facilitating better internalization into target cells.

Can you reduce the immunogenicity of non-human sulphatases?

Yes. Through surface engineering and epitope shielding, we can replace highly immunogenic surface residues with neutral counterparts to "hide" the enzyme from the host's immune system.

What is the significance of the FGly modification?

Formylglycine (FGly) is a unique post-translational modification required in the active site of all sulphatases. We engineer expression systems to maximize this conversion for high-potency enzyme production.

What methods do you use for screening therapeutic variants?

We employ high-throughput fluorescence-based assays and mass spectrometry to measure the hydrolysis of sulfated sugars and steroids under simulated physiological conditions.

Can you engineer sulphatases for blood-brain barrier (BBB) crossing?

While challenging, we offer enzyme fusion services to attach BBB-shuttle peptides or antibodies that facilitate transcytosis into the central nervous system.

How long is a typical sulphatase optimization project?

Therapeutic optimization typically requires 25-40 weeks, depending on the requirements for pH shifting and cellular validation studies.

Do you offer customized expression and purification for these enzymes?

Yes, we provide specialized enzyme expression and purification services in mammalian cell lines to ensure proper glycosylation and folding.